A Prospective, Blinded (Evaluators and Subjects Blinded), Randomized Controlled Phase I Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Liposome-encapsulated Deoxycholic Acid for Injection (HY-2003) Administered by Subcutaneous Fat Layer Injection in the Subjects With Excessive Submental Fat Accumulation
Latest Information Update: 15 Apr 2025
At a glance
- Drugs HY 2003 (Primary)
- Indications Subcutaneous fat disorders
- Focus Adverse reactions
- Sponsors Sichuan Huiyu Pharmaceutical
Most Recent Events
- 10 Apr 2025 Status changed from not yet recruiting to recruiting.
- 10 Jan 2025 New trial record